EGFR and lung adenocarcinoma: Here, we present 2 patients with advanced lung adenocarcinoma harboring EGFR ex20ins mutation who responded well to first-line furmonertinib, achieving progression-free survival (PFS) of 8.13 months and 10.90 months, respectively.